Orchestra Current Deferred Revenue vs Cash And Short Term Investments Analysis

OBIO Stock

5.26 0.08 1.50%

Orchestra BioMed financial indicator trend analysis is much more than just breaking down Orchestra BioMed Holdings prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Orchestra BioMed Holdings is a good investment. Please check the relationship between Orchestra BioMed Current Deferred Revenue and its Cash And Short Term Investments accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Orchestra BioMed Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

Current Deferred Revenue vs Cash And Short Term Investments

Current Deferred Revenue vs Cash And Short Term Investments Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Orchestra BioMed Holdings Current Deferred Revenue account and Cash And Short Term Investments. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Orchestra BioMed's Current Deferred Revenue and Cash And Short Term Investments is -0.54. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Cash And Short Term Investments in the same time period over historical financial statements of Orchestra BioMed Holdings, assuming nothing else is changed. The correlation between historical values of Orchestra BioMed's Current Deferred Revenue and Cash And Short Term Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Orchestra BioMed Holdings are associated (or correlated) with its Cash And Short Term Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash And Short Term Investments has no effect on the direction of Current Deferred Revenue i.e., Orchestra BioMed's Current Deferred Revenue and Cash And Short Term Investments go up and down completely randomly.

Correlation Coefficient

-0.54

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Orchestra BioMed Holdings balance sheet. This account contains Orchestra BioMed investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Orchestra BioMed Holdings fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.

Most indicators from Orchestra BioMed's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Orchestra BioMed Holdings current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Orchestra BioMed Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

As of the 14th of December 2024, Selling General Administrative is likely to drop to about 14.6 M. Issuance Of Capital Stock is expected to grow at the current pace this year

	2021	2023	2024 (projected)
Depreciation And Amortization	181K	287K	227.4K
Interest Income	50K	3.8M	4.0M

Depreciation And Amortization Interest Income

Orchestra BioMed fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab
Total Assets		-0.32	-0.78	0.11	0.93	0.71	-0.53	0.93	-0.52	-0.63	-0.77	0.87	0.69	0.89	0.64	-0.93	0.98	1.0	-0.73	0.37	1.0	-0.9	0.87	0.75	0.41	-0.93
Short Long Term Debt Total	-0.32		0.84	0.88	-0.58	-0.79	0.54	-0.34	0.92	0.82	0.81	-0.3	-0.33	-0.22	0.29	0.55	-0.35	-0.33	0.64	-0.84	-0.3	0.63	-0.14	-0.85	-0.74	0.61
Other Current Liab	-0.78	0.84		0.53	-0.9	-0.94	0.65	-0.75	0.92	0.89	0.96	-0.68	-0.62	-0.64	-0.16	0.88	-0.8	-0.78	0.83	-0.79	-0.76	0.92	-0.57	-0.97	-0.72	0.93
Total Current Liabilities	0.11	0.88	0.53		-0.16	-0.46	0.17	0.14	0.77	0.63	0.44	0.18	-0.19	0.27	0.7	0.1	0.04	0.09	0.23	-0.81	0.15	0.2	0.34	-0.53	-0.46	0.18
Total Stockholder Equity	0.93	-0.58	-0.9	-0.16		0.82	-0.67	0.92	-0.66	-0.77	-0.94	0.88	0.59	0.86	0.49	-1.0	0.87	0.92	-0.86	0.47	0.93	-0.99	0.83	0.92	0.6	-0.97
Other Liab	0.71	-0.79	-0.94	-0.46	0.82		-0.84	0.79	-0.82	-0.68	-0.92	0.74	0.37	0.7	0.29	-0.83	0.74	0.7	-0.92	0.67	0.72	-0.87	0.63	0.87	0.9	-0.91
Net Tangible Assets	-0.53	0.54	0.65	0.17	-0.67	-0.84		-0.78	0.41	0.28	0.78	-0.82	0.12	-0.77	-0.55	0.72	-0.49	-0.49	0.95	-0.18	-0.59	0.75	-0.73	-0.63	-0.94	0.74
Property Plant And Equipment Net	0.93	-0.34	-0.75	0.14	0.92	0.79	-0.78		-0.43	-0.47	-0.81	0.99	0.39	0.99	0.77	-0.95	0.88	0.91	-0.89	0.22	0.96	-0.93	0.97	0.73	0.63	-0.94
Current Deferred Revenue	-0.52	0.92	0.92	0.77	-0.66	-0.82	0.41	-0.43		0.91	0.79	-0.33	-0.65	-0.28	0.23	0.62	-0.6	-0.54	0.59	-0.96	-0.48	0.68	-0.2	-0.87	-0.6	0.71
Net Debt	-0.63	0.82	0.89	0.63	-0.77	-0.68	0.28	-0.47	0.91		0.82	-0.39	-0.78	-0.35	0.16	0.71	-0.63	-0.65	0.53	-0.84	-0.57	0.75	-0.29	-0.92	-0.39	0.72
Retained Earnings	-0.77	0.81	0.96	0.44	-0.94	-0.92	0.78	-0.81	0.79	0.82		-0.79	-0.45	-0.74	-0.29	0.93	-0.73	-0.76	0.92	-0.6	-0.77	0.96	-0.69	-0.98	-0.79	0.93
Accounts Payable	0.87	-0.3	-0.68	0.18	0.88	0.74	-0.82	0.99	-0.33	-0.39	-0.79		0.26	1.0	0.82	-0.92	0.8	0.85	-0.9	0.1	0.92	-0.9	0.99	0.68	0.65	-0.89
Cash	0.69	-0.33	-0.62	-0.19	0.59	0.37	0.12	0.39	-0.65	-0.78	-0.45	0.26		0.28	-0.03	-0.54	0.74	0.73	-0.17	0.67	0.61	-0.52	0.25	0.59	-0.07	-0.57
Non Current Assets Total	0.89	-0.22	-0.64	0.27	0.86	0.7	-0.77	0.99	-0.28	-0.35	-0.74	1.0	0.28		0.86	-0.91	0.82	0.86	-0.85	0.06	0.93	-0.87	1.0	0.63	0.58	-0.87
Non Currrent Assets Other	0.64	0.29	-0.16	0.7	0.49	0.29	-0.55	0.77	0.23	0.16	-0.29	0.82	-0.03	0.86		-0.57	0.55	0.6	-0.54	-0.42	0.7	-0.49	0.89	0.14	0.27	-0.51
Other Assets	-0.93	0.55	0.88	0.1	-1.0	-0.83	0.72	-0.95	0.62	0.71	0.93	-0.92	-0.54	-0.91	-0.57		-0.88	-0.92	0.89	-0.41	-0.94	0.99	-0.88	-0.89	-0.63	0.97
Long Term Debt	0.98	-0.35	-0.8	0.04	0.87	0.74	-0.49	0.88	-0.6	-0.63	-0.73	0.8	0.74	0.82	0.55	-0.88		0.98	-0.69	0.48	0.96	-0.85	0.79	0.73	0.42	-0.92
Cash And Short Term Investments	1.0	-0.33	-0.78	0.09	0.92	0.7	-0.49	0.91	-0.54	-0.65	-0.76	0.85	0.73	0.86	0.6	-0.92	0.98		-0.7	0.4	0.99	-0.89	0.84	0.75	0.38	-0.92
Net Receivables	-0.73	0.64	0.83	0.23	-0.86	-0.92	0.95	-0.89	0.59	0.53	0.92	-0.9	-0.17	-0.85	-0.54	0.89	-0.69	-0.7		-0.36	-0.77	0.91	-0.81	-0.82	-0.91	0.9
Common Stock Shares Outstanding	0.37	-0.84	-0.79	-0.81	0.47	0.67	-0.18	0.22	-0.96	-0.84	-0.6	0.1	0.67	0.06	-0.42	-0.41	0.48	0.4	-0.36		0.31	-0.48	-0.03	0.71	0.43	-0.54
Short Term Investments	1.0	-0.3	-0.76	0.15	0.93	0.72	-0.59	0.96	-0.48	-0.57	-0.77	0.92	0.61	0.93	0.7	-0.94	0.96	0.99	-0.77	0.31		-0.91	0.91	0.73	0.46	-0.93
Non Current Liabilities Total	-0.9	0.63	0.92	0.2	-0.99	-0.87	0.75	-0.93	0.68	0.75	0.96	-0.9	-0.52	-0.87	-0.49	0.99	-0.85	-0.89	0.91	-0.48	-0.91		-0.83	-0.93	-0.69	0.98
Inventory	0.87	-0.14	-0.57	0.34	0.83	0.63	-0.73	0.97	-0.2	-0.29	-0.69	0.99	0.25	1.0	0.89	-0.88	0.79	0.84	-0.81	-0.03	0.91	-0.83		0.58	0.52	-0.83
Other Current Assets	0.75	-0.85	-0.97	-0.53	0.92	0.87	-0.63	0.73	-0.87	-0.92	-0.98	0.68	0.59	0.63	0.14	-0.89	0.73	0.75	-0.82	0.71	0.73	-0.93	0.58		0.68	-0.89
Other Stockholder Equity	0.41	-0.74	-0.72	-0.46	0.6	0.9	-0.94	0.63	-0.6	-0.39	-0.79	0.65	-0.07	0.58	0.27	-0.63	0.42	0.38	-0.91	0.43	0.46	-0.69	0.52	0.68		-0.7
Total Liab	-0.93	0.61	0.93	0.18	-0.97	-0.91	0.74	-0.94	0.71	0.72	0.93	-0.89	-0.57	-0.87	-0.51	0.97	-0.92	-0.92	0.9	-0.54	-0.93	0.98	-0.83	-0.89	-0.7

Click cells to compare fundamentals

Orchestra BioMed Account Relationship Matchups

Pair Trading with Orchestra BioMed

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Orchestra BioMed position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Orchestra BioMed will appreciate offsetting losses from the drop in the long position's value.

Moving against Orchestra Stock

0.61	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.43	LLY	Eli Lilly	Pair Corr
0.38	PFE	Pfizer Inc Fiscal Year End 4th of February 2025	Pair Corr

The ability to find closely correlated positions to Orchestra BioMed could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Orchestra BioMed when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Orchestra BioMed - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Orchestra BioMed Holdings to buy it.

The correlation of Orchestra BioMed is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Orchestra BioMed moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Orchestra BioMed Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Orchestra BioMed can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Orchestra BioMed Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Orchestra BioMed's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Orchestra Biomed Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Orchestra Biomed Holdings Stock:

How To Invest In Orchestra

Details

Is Orchestra Stock a good investment?

Details

What is Orchestra BioMed's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Orchestra BioMed Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Orchestra BioMed. If investors know Orchestra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Orchestra BioMed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.60)

Revenue Per Share

0.073

Quarterly Revenue Growth

1.356

Return On Assets

(0.39)

Return On Equity

(0.92)

The market value of Orchestra BioMed Holdings is measured differently than its book value, which is the value of Orchestra that is recorded on the company's balance sheet. Investors also form their own opinion of Orchestra BioMed's value that differs from its market value or its book value, called intrinsic value, which is Orchestra BioMed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Orchestra BioMed's market value can be influenced by many factors that don't directly affect Orchestra BioMed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Orchestra BioMed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Orchestra BioMed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Orchestra BioMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Orchestra Current Deferred Revenue vs Cash And Short Term Investments Analysis

Current Deferred Revenue vs Cash And Short Term Investments

Current Deferred Revenue vs Cash And Short Term Investments Correlation Analysis

Correlation Coefficient

Current Deferred Revenue

Cash And Short Term Investments

Orchestra BioMed fundamental ratios Correlations

Orchestra BioMed Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Pair Trading with Orchestra BioMed

Moving against Orchestra Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Short Term Investments	+ 1.0	Total Assets
Non Current Assets Total	+ 1.0	Accounts Payable
Inventory	+ 1.0	Non Current Assets Total
Accounts Payable	+ 0.99	Property Plant And Equipment Net
Non Current Assets Total	+ 0.99	Property Plant And Equipment Net

Other Assets	- 1.0	Total Stockholder Equity
Non Current Liabilities Total	- 0.99	Total Stockholder Equity
Other Current Assets	- 0.98	Retained Earnings
Total Liab	- 0.97	Total Stockholder Equity
Other Current Assets	- 0.97	Other Current Liab
Common Stock Shares Outstanding	- 0.96	Current Deferred Revenue